Johnson & Johnson (J&J) has reported a strong start to 2026, exceeding analyst expectations with robust first-quarter earnings and revising its full-year growth forecast upwards. The pharmaceutical giant’s Chief Executive Officer, Joaquin Duato, expressed optimism about the company’s trajectory, pinpointing the newly approved psoriasis pill, Icotyde, as a key driver for accelerated growth into the next decade. This positive outlook comes despite the ongoing impact of biosimilar competition for its blockbuster drug, Stelara (ustekinumab).
First Quarter Performance Exceeds Expectations
In the first quarter of 2026, Johnson & Johnson announced total sales of $24.1 billion, a notable 9.9% increase compared to the same period in 2025. This figure surpassed the consensus analyst estimate of $23.61 billion. The company’s operational growth stood at a healthy 6.4%. Furthermore, J&J’s adjusted earnings per share (EPS) reached $2.70, edging out Wall Street’s projections of $2.68, signaling strong financial performance and effective cost management.
The impressive Q1 sales were primarily fueled by the company’s innovative medicines segment, which experienced an 11.2% surge in revenue year-over-year, reaching $15.4 billion. This segment’s success underscores J&J’s strategic focus on developing and commercializing cutting-edge therapies across critical therapeutic areas.
Key Growth Drivers Within the Pharmaceutical Portfolio
Several disease areas contributed significantly to the surge in the innovative medicines portfolio. Oncology emerged as a major revenue generator, with J&J’s multiple myeloma treatments, including Darzalex (daratumumab) and Carvykti (ciltacabtagene autoleucel), collectively generating $6.97 billion in the first quarter. These therapies have become cornerstones in the treatment landscape for multiple myeloma, demonstrating J&J’s strong presence and innovation in the oncology space.
The neuroscience division also exhibited robust growth, largely propelled by the performance of Spravato (esketamine), a treatment for treatment-resistant depression (TRD). Spravato’s innovative mechanism of action and its effectiveness in a challenging patient population have positioned it as a vital therapeutic option, contributing to J&J’s expanding neuroscience portfolio.
Within the immunology segment, Tremfya (guselkumab) played a crucial role in bolstering sales. As a selective IL-23 inhibitor, Tremfya has demonstrated significant efficacy in treating moderate-to-severe plaque psoriasis and psoriatic arthritis, addressing unmet needs in these chronic conditions.
Navigating Biosimilar Competition
Despite the overall positive financial results, Johnson & Johnson continues to navigate the challenges posed by the loss of market exclusivity for Stelara. Stelara, a dual inhibitor of IL-12 and IL-23, has been a significant revenue driver for J&J for many years. However, the introduction of biosimilar versions in key markets has inevitably led to some erosion of its market share and a dampening effect on overall growth during this period. The company’s ability to maintain strong growth in the face of this competition highlights the strength and diversification of its broader pharmaceutical pipeline.
Elevated 2026 Outlook and the Promise of Icotyde
Buoyed by its strong first-quarter performance and the promising outlook for its pipeline, Johnson & Johnson has revised its full-year 2026 operational sales growth forecast upwards. The company now anticipates growth in the range of 5.6% to 6.6%, an increase from the previously projected 5.4% to 6.4%. This upward revision signals increased confidence in J&J’s ability to achieve its financial objectives for the year.
Central to this optimistic outlook is the anticipated impact of Icotyde (icotrokinra), J&J’s newly approved oral medication for plaque psoriasis. CEO Joaquin Duato explicitly stated that the company is on track to achieve double-digit growth by the end of the decade, with Icotyde expected to fill the void left by Stelara’s declining sales. Analysts at GlobalData have projected a "blockbuster" future for Icotyde, forecasting global sales to reach an impressive $4.4 billion by 2032. This projection underscores the significant market potential for an effective and convenient oral treatment for psoriasis.
Icotyde: A Strategic Pillar for Future Growth
The approval and launch of Icotyde represent a pivotal moment for Johnson & Johnson’s immunology franchise. As an IL-23 inhibitor delivered in an oral tablet form, Icotyde offers a significant advancement in patient convenience and accessibility compared to injectable biologics. This oral administration is expected to be a key differentiator in a competitive market, potentially appealing to a broader patient population seeking less invasive treatment options.
In a previous discussion with Pharmaceutical Technology, GlobalData analyst Stephanie Ngan highlighted the strategic advantage of Icotyde’s approval for both adult and adolescent patient populations. "This immediately casts a wider net for the drug’s early and broad uptake," Ngan noted, emphasizing the drug’s potential to capture a substantial market share from its initial launch. The ability to treat younger patients also extends the potential lifecycle and commercial success of the drug.
The development and commercialization of Icotyde are part of J&J’s broader strategy to maintain leadership in immunology and address chronic inflammatory diseases with innovative therapies. The drug’s mechanism of action targets a key pathway involved in the pathogenesis of psoriasis, offering a targeted approach to disease management.
Navigating the Pricing Landscape: The MFN Deal
Johnson & Johnson’s strategic ambitions are unfolding against the backdrop of complex pharmaceutical pricing regulations, particularly in the United States. The company is operating under its Most Favored Nation (MFN) pricing deal with the White House. This agreement mandates that certain branded medicines within J&J’s portfolio will experience a price reduction in the U.S. In exchange, these drugs are exempted from the imposition of 100% tariffs.
This MFN deal, while potentially impacting short-term revenue on specific products, is designed to provide a degree of predictability in pricing and market access. For J&J, the ability to secure exemptions from tariffs offers a strategic advantage in managing its global supply chain and overall cost structure. The long-term implications of this pricing framework on drug development investment and market dynamics are a subject of ongoing observation within the industry.
Background and Chronology
The strong Q1 2026 performance builds upon a series of strategic moves and pipeline developments by Johnson & Johnson over the past few years. The company has consistently invested heavily in research and development, focusing on areas with high unmet medical needs and significant market potential.
- Early 2020s: Johnson & Johnson continued to advance its oncology and immunology pipelines, with Stelara remaining a significant contributor to sales. Discussions around biosimilar entry for Stelara began to gain traction.
- Mid-2020s: Significant progress was made in the development of Icotyde. Clinical trials demonstrated its efficacy and safety profile for plaque psoriasis. Regulatory submissions were initiated in key markets.
- Late 2025/Early 2026: Johnson & Johnson secured regulatory approvals for Icotyde in major markets, including the United States and Europe. The drug began its phased launch. Concurrently, biosimilar versions of Stelara entered the market, initiating the expected revenue shift.
- Q1 2026: The company reported strong financial results, exceeding expectations, with significant contributions from its oncology, neuroscience, and immunology portfolios, including early sales from Icotyde. The company revised its 2026 growth outlook upwards.
Broader Industry Implications and Analysis
Johnson & Johnson’s performance and strategic outlook offer several insights into the current state and future direction of the pharmaceutical industry.
- Pipeline Power: The company’s ability to deliver accelerated growth despite patent expirations underscores the critical importance of a robust and diversified pipeline. Innovations like Icotyde are essential for replacing revenue streams from mature products.
- Oral Formulations as a Competitive Edge: The success anticipated for Icotyde highlights the growing demand for convenient oral medications, particularly in chronic disease management. This trend is likely to drive further research and development into oral delivery systems for complex therapies.
- Navigating the Biosimilar Landscape: J&J’s experience with Stelara demonstrates the ongoing challenge of managing biosimilar competition. Pharmaceutical companies must strategically plan for market exclusivity losses and invest in new product launches to mitigate the impact.
- Pricing and Access Dynamics: The MFN deal illustrates the increasing influence of governmental policies on pharmaceutical pricing. Companies are actively seeking strategies to balance commercial viability with regulatory pressures and market access demands.
- Long-Term Growth Strategy: J&J’s focus on achieving double-digit growth by the end of the decade signals an ambitious long-term vision. This requires sustained innovation, strategic acquisitions, and efficient commercial execution.
Future Outlook
With a strengthened 2026 outlook and the promising launch of Icotyde, Johnson & Johnson is well-positioned to maintain its leadership in the pharmaceutical sector. The company’s diversified portfolio, commitment to innovation, and strategic adaptation to market dynamics suggest a trajectory of sustained growth and value creation. The success of Icotyde will be a key indicator of J&J’s ability to effectively transition its revenue streams and capitalize on emerging therapeutic opportunities. The company’s continued investment in research and development, particularly in areas like immunology and oncology, will be crucial in shaping its future success and its ability to address evolving global health challenges.
Leave a Reply